Female patients report comparable results to males after the implantation of an aragonite-based scaffold for the treatment of knee chondral and osteochondral defects: a gender-based analysis of a RCT at 4 years' follow-up.

IF 3 2区 医学 Q1 ORTHOPEDICS
Elizaveta Kon, Francesca De Caro, Vinod Dasa, Jason M Scopp, Berardo Di Matteo, David Flanigan, Nogah Shabshin, Sabrina Strickland, Nir Altschuler
{"title":"Female patients report comparable results to males after the implantation of an aragonite-based scaffold for the treatment of knee chondral and osteochondral defects: a gender-based analysis of a RCT at 4 years' follow-up.","authors":"Elizaveta Kon, Francesca De Caro, Vinod Dasa, Jason M Scopp, Berardo Di Matteo, David Flanigan, Nogah Shabshin, Sabrina Strickland, Nir Altschuler","doi":"10.1186/s10195-025-00829-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The aim of the study was to provide a gender-based analysis of the results of a large, multi-centre randomized controlled trial (RCT) comparing a novel cell-free aragonite-based scaffold with the standard of care (i.e. debridement/microfractures) for the treatment of chondral/osteochondral defects in knees with or without concurrent osteoarthritis.</p><p><strong>Materials and methods: </strong>A total of 251 patients were included: 167 patients in the scaffold group and 84 in the control. In the scaffold group, there were 105 males and 59 females, whereas the control group consisted of 51 males and 32 females. Patients were evaluated up to 48 months after the treatment. The primary endpoint was the change from baseline to 48 months in the KOOS overall score. Treatment failures were defined as any secondary invasive intervention, including intra-articular injection or any surgery in the treated joint. All patients underwent magnetic resonance imaging (MRI) at 12 and 24 months to assess the percentage of defect fill after surgery.</p><p><strong>Results: </strong>Both males and females in the scaffold group achieved significantly better results than controls in any KOOS subscale, as well as in KOOS overall, up to the final 48 months follow-up. Outcomes reported by females were non-inferior to those of males in the implant group. At 24 months' MRI evaluation, 86.2% of male patients in the scaffold group presented at least 75% defect fill compared with 32.6% in the control group. In the scaffold group, 87.6% of female patients presented at least 75% defect fill, compared with 28% in the control group (p < 0.0001 in both cases). Responders' rate and failure rate were also significantly better in the scaffold group for both males and females.</p><p><strong>Conclusion: </strong>The aragonite scaffold outperformed the control group at 48 months' evaluation. The gender-based analysis proved that males and females in the scaffold group presented comparable clinical and radiographical results, both significantly better than their counterparts treated by debridement/microfractures.</p><p><strong>Level of evidence: </strong>I-Randomized controlled trial.</p><p><strong>Trial registration: </strong>Clinicaltrial.gov ID: NCT03299959 (registered on 14 September 2017).</p>","PeriodicalId":48603,"journal":{"name":"Journal of Orthopaedics and Traumatology","volume":"26 1","pages":"17"},"PeriodicalIF":3.0000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906925/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Orthopaedics and Traumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s10195-025-00829-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The aim of the study was to provide a gender-based analysis of the results of a large, multi-centre randomized controlled trial (RCT) comparing a novel cell-free aragonite-based scaffold with the standard of care (i.e. debridement/microfractures) for the treatment of chondral/osteochondral defects in knees with or without concurrent osteoarthritis.

Materials and methods: A total of 251 patients were included: 167 patients in the scaffold group and 84 in the control. In the scaffold group, there were 105 males and 59 females, whereas the control group consisted of 51 males and 32 females. Patients were evaluated up to 48 months after the treatment. The primary endpoint was the change from baseline to 48 months in the KOOS overall score. Treatment failures were defined as any secondary invasive intervention, including intra-articular injection or any surgery in the treated joint. All patients underwent magnetic resonance imaging (MRI) at 12 and 24 months to assess the percentage of defect fill after surgery.

Results: Both males and females in the scaffold group achieved significantly better results than controls in any KOOS subscale, as well as in KOOS overall, up to the final 48 months follow-up. Outcomes reported by females were non-inferior to those of males in the implant group. At 24 months' MRI evaluation, 86.2% of male patients in the scaffold group presented at least 75% defect fill compared with 32.6% in the control group. In the scaffold group, 87.6% of female patients presented at least 75% defect fill, compared with 28% in the control group (p < 0.0001 in both cases). Responders' rate and failure rate were also significantly better in the scaffold group for both males and females.

Conclusion: The aragonite scaffold outperformed the control group at 48 months' evaluation. The gender-based analysis proved that males and females in the scaffold group presented comparable clinical and radiographical results, both significantly better than their counterparts treated by debridement/microfractures.

Level of evidence: I-Randomized controlled trial.

Trial registration: Clinicaltrial.gov ID: NCT03299959 (registered on 14 September 2017).

在植入文石支架治疗膝关节软骨和骨软骨缺损后,女性患者报告的结果与男性相当:一项4年随访的基于性别的随机对照试验分析。
背景:该研究的目的是对一项大型多中心随机对照试验(RCT)的结果进行基于性别的分析,该试验比较了一种新型无细胞文石支架与标准护理(即清创/微骨折)治疗伴有或不伴有骨关节炎的膝关节软骨/骨软骨缺损的效果。材料与方法:共纳入251例患者:支架组167例,对照组84例。支架组男性105例,女性59例,对照组男性51例,女性32例。患者在治疗后48个月接受评估。主要终点是kos总评分从基线到48个月的变化。治疗失败被定义为任何二次侵入性干预,包括关节内注射或治疗关节的任何手术。所有患者在术后12个月和24个月进行磁共振成像(MRI)以评估缺损填充率。结果:截至最后48个月的随访,支架组的男性和女性在任何kos分量表以及总体kos方面的结果均明显优于对照组。在种植体组中,女性报告的结果并不逊于男性。在24个月的MRI评估中,支架组中86.2%的男性患者出现至少75%的缺损填充,而对照组为32.6%。在支架组中,87.6%的女性患者的缺损充足率至少为75%,而对照组为28% (p)。结论:文石支架在48个月的评估中优于对照组。基于性别的分析证明,支架组男性和女性的临床和影像学结果相当,均明显优于清创/微骨折组。证据水平:i -随机对照试验。试验注册:Clinicaltrial.gov ID: NCT03299959(注册于2017年9月14日)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Orthopaedics and Traumatology
Journal of Orthopaedics and Traumatology Medicine-Orthopedics and Sports Medicine
CiteScore
4.30
自引率
0.00%
发文量
56
审稿时长
13 weeks
期刊介绍: The Journal of Orthopaedics and Traumatology, the official open access peer-reviewed journal of the Italian Society of Orthopaedics and Traumatology, publishes original papers reporting basic or clinical research in the field of orthopaedic and traumatologic surgery, as well as systematic reviews, brief communications, case reports and letters to the Editor. Narrative instructional reviews and commentaries to original articles may be commissioned by Editors from eminent colleagues. The Journal of Orthopaedics and Traumatology aims to be an international forum for the communication and exchange of ideas concerning the various aspects of orthopaedics and musculoskeletal trauma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信